| 1. |
GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10513): 1873-1922.
|
| 2. |
Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023[J]. J Am Coll Cardiol, 2025, 86(22): 2167-2243.
|
| 3. |
National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2023: an updated summary[J]. Biomed Environ Sci, 2024, 37(9): 949-992.
|
| 4. |
Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association[J]. Circulation, 2023, 148(20): 1606-1635.
|
| 5. |
GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10518): 2461-2482.
|
| 6. |
Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J/OL]. Kidney Int, 2024, 105(4S): S117-S314. DOI: 10.1016/j.kint.2023.10.018.
|
| 7. |
Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke, 2024, 55(12): e344-e424. DOI: 10.1161/STR.0000000000000475.
|
| 8. |
Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension[J]. J Hypertens, 2023, 41(12): 1874-2071.
|
| 9. |
Brauer M, Roth GA, Aravkin AY, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2162-2203.
|
| 10. |
中華人民共和國國家衛生健康委員會醫政司. 肥胖癥中國診療指南(2024年版)[J]. 協和醫學雜志, 2025, 16(1): 90-108.Department of Medical Administration, National Health Commission of the People's Republic of China. Chinese guidelines for the clinical management of obesity (2024 edition)[J]. Med J Peking Union Med Coll Hosp, 2025, 16(1): 90-108.
|
| 11. |
Xu SK, Liu ZY, Tang M, et al. Burden, risk factors, and projections of ischemic heart disease in China (1990-2021): findings from the 2021 GBD study[J/OL]. Front Cardiovasc Med, 2025, 12: 1549147. DOI: 10.3389/fcvm.2025.1549147.
|
| 12. |
Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement[J/OL]. Lancet, 2016, 388(10062): e19-e23. DOI: 10.1016/S0140-6736(16)30388-9.
|
| 13. |
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability, disability-adjusted life-years, and healthy life expectancy for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2133-2161.
|
| 14. |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204-1222.
|
| 15. |
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223-1249.
|
| 16. |
GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy, and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1160-1203.
|
| 17. |
Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse[J/OL]. J Open Source Softw, 2019, 4(43): 1686. DOI: 10.21105/joss.01686.
|
| 18. |
Hyndman RJ, Khandakar Y. Automatic time series forecasting: the forecast package for R[J]. J Stat Softw, 2008, 27(3): 1-22.
|
| 19. |
Ljung GM, Box GEP. On a measure of lack of fit in time series models[J]. Biometrika, 1978, 65(2): 297-303.
|
| 20. |
NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet, 2021, 398(10304): 957-980.
|
| 21. |
Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension[J]. N Engl J Med, 2021, 385(14): 1268-1279.
|
| 22. |
Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death[J]. N Engl J Med, 2021, 385(12): 1067-1077.
|
| 23. |
Li S, Liu Z, Joseph P, et al. Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy[J]. Eur Heart J, 2022, 43(30): 2852-2863.
|
| 24. |
Wang H, Zhang H, Zou Z. Changing profiles of cardiovascular disease and risk factors in China: a secondary analysis for the Global Burden of Disease Study 2019[J]. Chin Med J (Engl), 2023, 136(20): 2431-2441.
|
| 25. |
NCD Risk Factor Collaboration. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants[J]. Lancet, 2024, 404(10467): 2077-2093.
|
| 26. |
NCD Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults[J]. Lancet, 2024, 403(10431): 1027-1050.
|
| 27. |
Chen Y, Yu W, Lv J, et al. Early adulthood BMI and cardiovascular disease: a prospective cohort study from the China Kadoorie Biobank[J/OL]. Lancet Public Health, 2024, 9(12): e1005-e1013. DOI: 10.1016/S2468-2667(24)00043-4.
|
| 28. |
Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446.
|
| 29. |
Empa-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2023, 388(2): 117-127.
|
| 30. |
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391(2): 109-121.
|
| 31. |
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis[J]. Eur Heart J, 2022, 43(6): 474-484.
|
| 32. |
Magnussen C, Ojeda FM, Leong DP, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality[J]. N Engl J Med, 2023, 389(14): 1273-1285.
|
| 33. |
Xie Z, Yu C, Cui Q, et al. Global burden of the key components of cardiovascular-kidney-metabolic syndrome[J]. J Am Soc Nephrol, 2025, 36(8): 1572-1584.
|
| 34. |
Zheng C, Cai A, Sun M, et al. Prevalence and mortality of cardiovascular-kidney-metabolic syndrome in China: a nationwide population-based study[J]. JACC Asia, 2025, 5(7): 898-910.
|
| 35. |
Tian F, Chen L, Qian Z, et al. Ranking age-specific modifiable risk factors for cardiovascular disease and mortality: evidence from a population-based longitudinal study[J/OL]. eClinicalMedicine, 2023, 64: 102230. DOI: 10.1016/j.eclinm.2023.102230.
|
| 36. |
Wen F, Wang J, Yang C, et al. Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study[J/OL]. Lancet Reg Health West Pac, 2025, 56: 101493. DOI: 10.1016/j.lanwpc.2025.101493.
|
| 37. |
Wang R, Wang Y, Lu J, et al. Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort[J]. Heart, 2025, 111(5): 205-211.
|
| 38. |
Sun Q, Yu D, Fan J, et al. Healthy lifestyle and life expectancy at age 30 years in the Chinese population: an observational study[J/OL]. Lancet Public Health, 2022, 7(12): e994-e1004. DOI: 10.1016/S2468-2667(22)00110-4.
|